"Their [patients'] personalized genetic data has been determined, and we are ready to move on to their treatment with joint efforts within literally one to one and a half months," Gintsburg said during a roundtable.
The Gamaleya National Research Center for Epidemiology and Microbiology is working on a personalized domestic cancer vaccine based on neoantigens. According to the center’s director, Alexander Ginzburg, it will begin to be administered experimentally in the coming months to a group of melanoma patients.